{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-26-001526","form_type":"8-K","ticker":"CRVS","cik":"0001626971","company_name":"Corvus Pharmaceuticals, Inc.","filed_at":"2026-03-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.677414+00:00","generated_at":"2026-05-15T13:32:03.979420+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Corvus Q4 net loss $12.3M; soquelitinib atopic dermatitis Ph1 75% EASI75; raises $189M","bullets":["Net loss for Q4 2025 was $12.3M; R&D expenses $9.9M (up from $6.0M in Q4 2024).","Cash $56.8M at Dec 31, 2025; $189.4M net from Jan 2026 offering extends runway into Q2 2028.","Cohort 4 atopic dermatitis: 75% soquelitinib patients achieved EASI 75 vs 20% placebo; 33% IGA 0/1 vs 0%.","Initiated Phase 2 atopic dermatitis trial in Q1 2026; ~200 patients, four dose arms, 12-week treatment.","Phase 3 PTCL registrational trial enrolling; soquelitinib granted Fast Track and Orphan Drug Designation."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-26-001526","json":"https://secwatch.observer/filing/0001171843-26-001526.json","markdown":"https://secwatch.observer/filing/0001171843-26-001526.md","text":"https://secwatch.observer/filing/0001171843-26-001526.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1626971/000117184326001526/0001171843-26-001526-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1626971/000117184326001526/f8k_031226.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T13:32:03.979420+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}